These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 34697424)
1. p21-Activated kinases as promising therapeutic targets in hematological malignancies. Wu A; Jiang X Leukemia; 2022 Feb; 36(2):315-326. PubMed ID: 34697424 [TBL] [Abstract][Full Text] [Related]
2. P21 activated kinase signaling in cancer. Rane CK; Minden A Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094 [TBL] [Abstract][Full Text] [Related]
3. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer. Shao YG; Ning K; Li F World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660 [TBL] [Abstract][Full Text] [Related]
8. Role of p-21-activated kinases in cancer progression. King H; Nicholas NS; Wells CM Int Rev Cell Mol Biol; 2014; 309():347-87. PubMed ID: 24529727 [TBL] [Abstract][Full Text] [Related]
9. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073 [TBL] [Abstract][Full Text] [Related]
10. PAK signaling in cancer. Ye DZ; Field J Cell Logist; 2012 Apr; 2(2):105-116. PubMed ID: 23162742 [TBL] [Abstract][Full Text] [Related]
12. Rho family GTPase signaling through type II p21-activated kinases. Chetty AK; Ha BH; Boggon TJ Cell Mol Life Sci; 2022 Nov; 79(12):598. PubMed ID: 36401658 [TBL] [Abstract][Full Text] [Related]
13. Pak protein kinases and their role in cancer. Dummler B; Ohshiro K; Kumar R; Field J Cancer Metastasis Rev; 2009 Jun; 28(1-2):51-63. PubMed ID: 19165420 [TBL] [Abstract][Full Text] [Related]
14. Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration. Ma Y; McCarty SK; Kapuriya NP; Brendel VJ; Wang C; Zhang X; Jarjoura D; Saji M; Chen CS; Ringel MD J Clin Endocrinol Metab; 2013 Aug; 98(8):E1314-22. PubMed ID: 23709653 [TBL] [Abstract][Full Text] [Related]
15. Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer. Yi C; Maksimoska J; Marmorstein R; Kissil JL Biochem Pharmacol; 2010 Sep; 80(5):683-9. PubMed ID: 20302846 [TBL] [Abstract][Full Text] [Related]
16. Inhibitors of p21-activated kinases (PAKs). Rudolph J; Crawford JJ; Hoeflich KP; Wang W J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869 [TBL] [Abstract][Full Text] [Related]
17. The p21-activated kinases in neural cytoskeletal remodeling and related neurological disorders. Zhang K; Wang Y; Fan T; Zeng C; Sun ZS Protein Cell; 2022 Jan; 13(1):6-25. PubMed ID: 33306168 [TBL] [Abstract][Full Text] [Related]
18. The Role of p21-Activated Kinases in Cancer and Beyond: Where Are We Heading? Liu H; Liu K; Dong Z Front Cell Dev Biol; 2021; 9():641381. PubMed ID: 33796531 [TBL] [Abstract][Full Text] [Related]
19. PAK as a therapeutic target in gastric cancer. Li X; Liu F; Li F Expert Opin Ther Targets; 2010 Apr; 14(4):419-33. PubMed ID: 20146633 [TBL] [Abstract][Full Text] [Related]
20. P21 activated kinases: structure, regulation, and functions. Rane CK; Minden A Small GTPases; 2014; 5():. PubMed ID: 24658305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]